Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.

MLA

Chang, Chun Chin, et al. “Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.” Cardiovascular Revascularization Medicine, vol. 20, no. 7, July 2019, pp. 577–82. EBSCOhost, https://doi.org/10.1016/j.carrev.2019.04.013.

APA

Chang, C. C., Onuma, Y., Achenbach, S., Barbato, E., Chevalier, B., Cook, S., Dudek, D., Escaned, J., Gori, T., Kočka, V., Tarantini, G., West, N. E. J., Morice, M.-C., Tijssen, J. G. P., van Geuns, R.-J., Smits, P. C., & COMPARE ABSORB trial investigators. (2019). Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial. Cardiovascular Revascularization Medicine, 20(7), 577–582. https://doi.org/10.1016/j.carrev.2019.04.013

Chicago

Chang, Chun Chin, Yoshinobu Onuma, Stephan Achenbach, Emanuele Barbato, Bernard Chevalier, Stéphane Cook, Dariusz Dudek, et al. 2019. “Absorb Bioresorbable Scaffold Versus Xience Metallic Stent for Prevention of Restenosis Following Percutaneous Coronary Intervention in Patients at High Risk of Restenosis: Rationale and Design of the COMPARE ABSORB Trial.” Cardiovascular Revascularization Medicine 20 (7): 577–82. doi:10.1016/j.carrev.2019.04.013.